Inverness’ even bigger bid for Biosite puts ball back in Beckman’s court
This article was originally published in The Gray Sheet
Executive Summary
Latest salvo in the bidding war for heart test maker Biosite comes from Inverness Medical Innovations, raising its offer to $92.50 per share. Biosite recently inked an amended deal with Beckman Coulter valued at $90 per share to match Inverness' prior unsolicited proposal. Biosite says it is weighing the latest Inverness offer (1"The Gray Sheet" May 7, 2007, In Brief)...
You may also be interested in...
Inverness and Biosite make it official
Definitive merger agreement calls for Inverness to buy heart test maker Biosite for $92.50 per share, valuing the company at roughly $1.58 billion based on Biosite's 17.1 million shares outstanding as of March 31. Announced May 17, the deal will require Biosite's payment of a $54 million breakup fee to its former merger partner Beckman Coulter, for which Biosite will be reimbursed by Inverness. Beckman Coulter had bid $90 per share, or about $1.54 billion based on Biosite's shares outstanding, and announced May 14 that it would not increase its offer. Diagnostics firm Inverness plans to "quickly leverage Biosite's strength in proprietary protein markers and robust cardiovascular platform together with [Inverness'] ongoing research and development efforts in the cardiac arena," states CEO Ron Zwanziger. The deal is expected to close in early summer (1"The Gray Sheet" May 14, 2007, In Brief)...
Beckman Coulter sweetens Biosite bid to $1.67 billion
Biosite suitor Inverness Medical Innovations is weighing its next move after its unsolicited $90-per-share offer for heart test maker Biosite is matched by Beckman Coulter. Biosite initially had agreed to be acquired by Beckman for $85 per share, or $1.55 billion, on March 24. However, Biosite subsequently determined that Inverness' April 4 bid was superior to the initial Beckman deal. An amended merger agreement between Biosite and Beckman announced May 2 is worth $1.67 billion, according to Biosite. Under the revised deal, Beckman's $90-per-share cash tender offer will be open until May 15. "In light of this development we are evaluating our alternatives," Inverness CEO Ron Zwanziger said during the firm's Q1 earnings call May 2 (1"The Gray Sheet" April 30, 2007, p. 10)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.